Abstract:Meilin Zhu, 1 Lingzhou Zhao, 2 Xia Lu 2 1 School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia, 750004, People's Republic of China; 2 Department of Nuclear Medicine, Northern Jiangsu People's Hospital, Clinical Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China Correspondence: Xia Lu, Department of Nuclear Medicine, Northern Jiangsu People's Hospital, Clinical Medical College, Yangzhou University, Yangzhou, 225001, People's Republic of China, Tel +86 18051061486, Email Purpose: Gold nanoparticles (Au NPs) are widely used as versatile templates to develop multifunctional nanosystems for disease diagnosis and treatment. Iodine can bind to gold via chemisorption, making this a simple method for labeling Au NPs with radioactive iodine. However, the evaluation of tumor radionuclide therapy is insufficient. In this study, we investigated the feasibility of 131 I-adsorbed Au NPs as novel nanoprobes for tumor radionuclide therapy. Materials and Methods: Radiolabeling was performed by mixing Au NPs and 131 I, and the radiochemical purity (RCP) and in vitro stability of 131 I-adsorbed Au NPs were analyzed under different conditions, including various temperatures, pH values, and 131 I concentrations. The tumor accumulation and therapeutic potential of 131 I-adsorbed Au NPs were assessed using a subcutaneous tumor model after intratumoral injection. Results: The data showed that the chemisorption of the Au NPs onto 131 I was instant, specific, and quantitative. The 131 I-adsorbed Au NPs exhibited high in vitro stability in different media, distinct inhibitory effects on tumor cells in vitro, good retention ability, and therapeutic effects after intratumoral injection into tumor-bearing mice in vivo. Conclusion: Our work demonstrates that chemisorption of Au NPs and radioiodine has great potential as a strategy for constructing various nanosystems for theranostic applications. Keywords: gold nanoparticles, iodine-131, chemisorption, radionuclide therapy Radionuclide therapy delivers cytotoxic levels of radiation to specific disease sites and has been widely applied in cancer treatment. 1,2 Unlike conventional radiation therapy, which targets tumors externally, radionuclide therapy uses therapeutic radiopharmaceuticals that specifically bind to tumor tissues at the cellular level, exerting ionizing radiation within tumor cells, causing double-strand DNA damage, and eventually leading to tumor apoptosis. 3,4 Therapeutic radiopharmaceuticals are composed of appropriate radionuclides and tumor target-specific moieties, including antibodies, peptides, and small molecules. 5 Although numerous therapeutic radionuclides have been developed for radionuclide therapy, including but not limited to iodine-125 ( 125 I), iodine-131 ( 131 I), rhenium-188 ( 188 Re), yttrium-90 ( 90 Y), lutetium-177 ( 177 Lu), astatine-211 ( 211 At) and radium-223 ( 223 Ra), 131 I is one of the most widely used therapies in clinical application due to its favorable physical properties, safety, and low cost. 6,7 Advances in cancer nanomedicine have accelerated the use of various nanoparticles (NPs) as versatile carriers for the development of therapeutic radiopharmaceuticals. 8–11 In particular, gold NPs (Au NPs) have emerged as attractive nanoplatforms for tumor radionuclide therapy because of their remarkable physicochemical properties. 12,13 Through facile surface modifications, Au NPs can be synchronously functionalized with targeting ligands and therapeutic radionuclides for superior cancer therapy, which improves tumor uptake and minimizes unnecessary radiation exposure to normal tissues. 14 Meanwhile, the β-particles emitted from radionuclides, such as 131 I, can be converted to X-rays via the Bremsstrahlung reaction; these X-rays have a much greater penetration depth than the emitted β-particles, which further strengthen the anti-tumor efficacy. 6,15,16 Therefore, radiolabeled Au NPs possessing synergistic effects in tumor treatment have attracted much interest. To date, we and several other groups have reported different forms of 131 I-labeled Au NPs as therapeutic radiopharmaceuticals for tumor therapy via intravenous or intratumoral injection. 17–20 For 131 I radiolabeling of Au NPs, certain functional groups are generally essential, such as tyrosine residues, which require appropriate modifications before radiolabeling. Although these modified Au NPs can be effectively labeled with 131< -Abstract Truncated-

In Vivo Imaging of T Cells Loaded with Gold Nanoparticles: a Pilot Study

Gold Nanocage-Based Photothermal Ablation Facilitates in Situ Vaccination for Melanoma Therapy.

Early Tumor Detection Afforded by in Vivo Imaging of Near-Infrared Ii Fluorescence

Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy.

Feasibility of Monitoring Tumor Response by Tracking Nanoparticle-Labelled T Cells Using X-ray Fluorescence Imaging—A Numerical Study

In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma

Radionuclide-labeled gold nanoparticles for nuclei-targeting internal radio-immunity therapy

EGF-coated Gold Nanoparticles Provide an Efficient Nano-Scale Delivery System for the Molecular Radiotherapy of EGFR-positive Cancer

Noninvasive In Vivo Imaging of T-Cells during Cancer Immunotherapy Using Rare-Earth Nanoparticles

Metabolic Radiolabeling and in Vivo PET Imaging of Cytotoxic T Lymphocytes to Guide Combination Adoptive Cell Transfer Cancer Therapy

Cell‐Derived Biogenetic Gold Nanoparticles for Sensitizing Radiotherapy and Boosting Immune Response against Cancer

Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response

Iodine-124 Labeled Gold Nanoclusters for Positron Emission Tomography Imaging in Lung Cancer Model.

ImmunoPET imaging of human CD8+ T cells with novel 68Ga-labeled nanobody companion diagnostic agents

Tumor Uptake of Hollow Gold Nanospheres After Intravenous and Intra-arterial Injection: PET/CT Study in a Rabbit VX2 Liver Cancer Model

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

In Vivo MR Imaging of Glioma Recruitment of Adoptive T-Cells Labeled with NaGdF4 -TAT Nanoprobes.

In vivo Photoacoustic Imaging of Tumor Using Gold Nanoparticles as Contrast Agent

Tumor Angiogenesis Targeted Radiosensitization Therapy using Gold Nanoprobes Guided by MRI/SPECT Imaging.

Ex Vivo Radiolabeling and In Vivo PET Imaging of T Cells Expressing Nuclear Reporter Genes

Direct Labeling of Gold Nanoparticles with Iodine-131 for Tumor Radionuclide Therapy